Dominique Tersago

Director Técnico/Científico/I+D en CANTARGIA AB .

Fortuna: - $ al 30/04/2024

62 años

Health Technology

Consumer Services

Cargos activos de Dominique Tersago

Empresas	Cargo	Inicio	Fin
CANTARGIA AB	Director Técnico/Científico/I+D	01/08/2022	-

Empresas	Cargo	Inicio	Fin
Exevir Bio BV Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium.	Director Técnico/Científico/I+D	01/07/2020	01/07/2022
Highlight Therapeutics SL Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain.	Director Técnico/Científico/I+D	01/04/2017	01/03/2020
ABLYNX	Director Técnico/Científico/I+D	01/07/2013	01/11/2015

University of Antwerp

Doctorate Degree

Internacional

Operativa

Chief Tech/Sci/R&D Officer	4
Doctorate Degree	1

Sectorial

Health Technology	5
Consumer Services	2

Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Empresas cotizadas	1
CANTARGIA AB	Health Technology

Empresas privadas	3
Ablynx NV Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium.	Health Technology
Highlight Therapeutics SL Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain.	Health Technology
Exevir Bio BV Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium.	Health Technology